BiotechTube

SGT-212

Phase 1Recruiting
1 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Friedreich's Ataxia (FA)

Conditions

Friedreich's Ataxia (FA)

Trial Timeline

Oct 22, 2025 → Feb 29, 2032

NCT ID
NCT07180355

About SGT-212

SGT-212 is a phase 1 stage product being developed by Solid Biosciences for Friedreich's Ataxia (FA). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07180355. Target conditions include Friedreich's Ataxia (FA).

What happened to similar drugs?

0 of 7 similar drugs in Friedreich's Ataxia (FA) were approved

Approved (0) Terminated (0) Active (7)
🔄Interferon γ-1bAmgenPhase 3
🔄interferon γ-1bAmgenPhase 3
🔄Interferon γ-1b + PlaceboAmgenPhase 3
🔄idebenone + PlaceboSanthera PharmaceuticalsPhase 3
🔄Idebenone + Idebenone + PlaceboSanthera PharmaceuticalsPhase 3
🔄IdebenoneSanthera PharmaceuticalsPhase 3
🔄Idebenone + PlaceboSanthera PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07180355Phase 1Recruiting

Competing Products

11 competing products in Friedreich's Ataxia (FA)

See all competitors
ProductCompanyStageHype Score
Interferon γ-1bAmgenPhase 3
40
interferon γ-1bAmgenPhase 3
40
Interferon γ-1b + PlaceboAmgenPhase 3
40
varenicline + placeboPfizerPhase 2/3
30
Lu AA24493 + PlaceboLundbeckPhase 2
32
OmeveloxoloneBiogenPre-clinical
30
Placebo + EPI-743 400 mg + EPI-743 200 mgPTC TherapeuticsPhase 2
32
idebenone + PlaceboSanthera PharmaceuticalsPhase 3
30
Idebenone + Idebenone + PlaceboSanthera PharmaceuticalsPhase 3
30
IdebenoneSanthera PharmaceuticalsPhase 3
30
Idebenone + PlaceboSanthera PharmaceuticalsPhase 3
30